NEONC Technologies Holdings, Inc. Appoints Dr. Alan Chiang to its Board of Directors
Rhea-AI Summary
NeOnc Technologies Holdings, Inc. (upcoming NASDAQ: NTHI) has appointed Dr. Alan Chiang to its Board of Directors. Dr. Chiang, a practicing neurosurgeon at Fu Jen Catholic University Hospital and Associate Professor of Neurosurgery, brings expertise in minimally invasive spine surgery, brain tumor treatment, and biotechnology innovation.
Currently serving at Fu Jen Catholic University Hospital in New Taipei City, Taiwan, Dr. Chiang previously held key positions at Mackay Memorial Hospital, including Chief of Neurosurgery Division and Deputy Chairman of Surgery Department. He holds a Ph.D. from the Free University of Berlin and conducts research on brain cancer, focusing on WWOX and Sonic Hedgehog (SHH) pathways in glioma and glioblastoma.
As an entrepreneur, Dr. Chiang founded Neucen Biomedical Inc. and Orion Biotech Inc. His appointment aims to support NeOnc's advancement of their patented drug, NEO100, targeting brain and central nervous system diseases.
Positive
- Appointment of board member with relevant expertise in neurosurgery and brain cancer research
- Addition of entrepreneurial experience with founding of two biotech companies
- Strategic alignment with company's focus on NEO100 drug development
- Upcoming NASDAQ listing indicates potential market expansion
Negative
- Pre-revenue company yet to be listed on NASDAQ
- Drug development still in clinical stage with uncertain outcomes
Dr. Chaing Expands NeOnc’s Expertise in Neurosurgery and Biotechnology
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, today announced that it has appointed Dr. Alan Chiang to its Board of Directors. Dr. Chiang, an esteemed neurosurgeon and entrepreneur, brings substantial expertise in minimally invasive spine surgery, brain tumor treatment, and biotechnology innovation.
“We are excited to welcome Dr. Chiang to our Board,” said Dr. Thomas Chen, CEO of NeOnc. “His distinguished expertise in neurosurgery, coupled with his extensive experience in clinical research and entrepreneurial achievement, will be invaluable as we advance the delivery of our patented drug, NEO100. His visionary approach and commitment to progress resonate deeply with our mission.”
Dr. Chiang is a practicing neurosurgeon at Fu Jen Catholic University Hospital in New Taipei City, Taiwan, where he also serves as an Associate Professor of Neurosurgery. Previously, he held pivotal roles at Mackay Memorial Hospital in Taipei, including Chief of the Division of Neurosurgery, and Deputy Chairman of the Department of Surgery. With a distinguished career in clinical practice and leadership, Dr. Chiang has earned recognition as a key contributor to both Taiwanese and international medical advancements.
Beyond his clinical expertise, Dr. Chiang holds a Ph.D. from the Free University of Berlin, and is a dedicated researcher with a focus on brain cancer. His work includes molecular studies on WWOX and Sonic Hedgehog (SHH) pathways in glioma and glioblastoma, areas critical to understanding and treating these aggressive cancers. As a visionary entrepreneur, he founded Neucen Biomedical Inc. and Orion Biotech Inc., underscoring his commitment to driving innovation in biotechnology and advancing medical science.
“It is a real privilege to join NeOnc, and I am eager to leverage my expertise in neurosurgery and biotechnology to support the Company’s mission of advancing groundbreaking healthcare solutions,” said Dr. Chiang. “This role presents an extraordinary opportunity to collaborate with visionary leaders dedicated to transforming patient outcomes.”
“Dr. Chiang’s dedication to advancing neurosurgical techniques, and his inspiring contributions to biotechnology bring a new dimension to our board,” said Amir Heshmatpour, Executive Chairman of NeOnc. “Dr. Chaing’s insights into the latest medical advancements, and commitment to improving patient care will play a critical role as we strive to innovate in the area of brain and central nervous system diseases.”
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a privately held clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonctech.com.
Important Cautions Regarding Forward Looking Statements
All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding our expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding our expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate," or similar
expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law.
“NEO100” is a registered trademark of NeOnc Technologies Holdings, Inc.
Company Contact:
Patrick Walters
Chief Operations Officer
NeOnc Technologies Holdings, Inc.
info@neonc.com
Investor Relations:
Roger Pondel / Laurie Berman
PondelWilkinson Inc.
(310) 279-5980
rpondel@pondel.com
lberman@pondel.com
FAQ
What expertise does Dr. Alan Chiang bring to NTHI's Board of Directors?
How will Dr. Chiang's appointment impact NTHI's drug development program?
What is Dr. Chiang's current role outside of NTHI?
When will NTHI be listed on the NASDAQ Global Market?
